Search Results
Found 7 results for "belgium" across articles, medicines, trials, companies and the glossary
Industry
The Resource Equation: Decoupling Water, Power, and the Shift in Ireland’s Data Centre and Life Sciences Footprint
An in-depth, fact-based analysis of water and power consumption across Ireland’s twin industrial pillars, the infrastructure bottlenecks, and the shifting geography of high-tech construction.
Industry
The €8.5 Billion Defense: Dutch Innovative Pharma Fights Back Against Cost-Control Policies
The Dutch Association for Innovative Medicines (VIG) releases a detailed report highlighting the sector\'s €8.5 billion gross added value, warning that cost-containment measures threaten patient access, clinical trials, and Europe\'s biopharma sovereignty.
Regulatory Affairs
GEODIS Expands Pharmaceutical Logistics in Poland: Securing Dual GDP and IATA CEIV Pharma Certifications
GEODIS has renewed its IATA CEIV Pharma accreditation in Warsaw and secured GDP certification for its Stryków Dobra contract logistics facility. This dual compliance milestone bolsters Poland’s status as a critical gateway in Europe’s pharmaceutical supply chain.
Pharmaceutical
The Cascade Effect: How US MFN and IRA Pricing Mandates Are Reshaping Drug Development, Launch Sequencing, and Ireland’s Life Sciences Sector
An in-depth analysis of how US Most Favored Nation (MFN) drug pricing proposals and the Inflation Reduction Act (IRA) are forcing pharmaceutical companies to restructure indication sequencing, ex-US launches, and global supply chains.
Regulatory Affairs
How Most Favored Nation (MFN) Pricing Impacts Drug Development & Launch Planning
An expert analysis of the strategic shifts required in global drug development, indication sequencing, and launch timelines in response to proposed Most Favored Nation pricing and the Inflation Reduction Act.
Biotechnology
Rare Disease Bottlenecks vs. Encouraging Clinical Trial Growth in Ireland
Despite encouraging growth in clinical trial activity, patients in Ireland face an average wait of 801 days for access to rare disease medicines, prompting calls for urgent systemic reform.
Industry
Europe's United Front: How the Beneluxa Initiative is Defending the Pharma Framework Against US Pricing Pressure
With the US pushing for individual drug pricing deals and Germany slashing healthcare spending, the Beneluxa Initiative represents five European nations calling for a unified, coordinated approach to protect Europe's pharmaceutical innovation and access to medicines in 2026.